Skip to main content
20 search results for:

FGFR inhibitors 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 20-04-2023 | Urothelial cancer | At a glance | Article

    At a glance: Second and later line immunotherapy for advanced urothelial carcinoma

    A summary of the key trial publications on the use of PD-1 pathway and CTLA-4 inhibitors alone or in combination in the second-line or later treatment of locally advanced and metastatic urothelial carcinoma. This independent article was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

  2. 06-08-2021 | Urothelial cancer | Feature | Article
    Updated January 2023

    At a glance: First-line immunotherapy for advanced urothelial carcinoma

    In this article, we provide an overview of the published trials of PD-1 pathway and CTLA-4 inhibitors – used as monotherapy, in combination with chemotherapy, or as maintenance – in the first-line treatment of locally advanced or metastatic urothelial cancer.

  3. 13-05-2022 | Urothelial cancer | News | Article

    Limited uptake of erdafitinib in real-world setting

    They highlight that use of the pan-FGFR inhibitor was low even though real-world survival outcomes were comparable with those from clinical trials, and suggest “drug toxicity, drug cost limiting access, paucity of data on optimal treatment sequencing, and inadequate FGFR testing” as possible reasons.

  4. play
    18-09-2021 | ESMO 2021 | Conference coverage | Video

    Promising early results for cetrelimab plus erdafitinib reported for advanced UC

    Thomas Powles explains why the interim results of the NORSE trial of first-line cetrelimab plus erdafitinib in FGFR-altered advanced urothelial cancer not only justify its continuance, but also point to the need for larger studies of the combination in this setting. This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

  5. 17-09-2021 | ESMO 2021 | Conference coverage | Article

    Cetrelimab–erdafitinib duo shows promise in advanced urothelial carcinoma

    Adding the novel anti-PD-1 agent cetrelimab to the pan-FGFR inhibitor erdafitinib doubles the response rate in cisplatin-ineligible patients with untreated locally advanced or metastatic urothelial cancer and FGFR alterations, indicate trial data.

  6. 23-06-2021 | ASCO 2021 | Conference coverage | Article

    FGFR alterations may help guide metastatic UC treatment

    Researchers have identified an association between the presence of  FGFR  alterations and an increased risk for progression in people with metastatic urothelial carcinoma receiving first-line PD-1 pathway inhibitors. This independent news story was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

  7. 17-04-2020 | Urothelial cancer | News | Article

    Infigratinib urothelial carcinoma response varies by tumor site

    Chelsea Osterman and Matthew Milowsky, from the University of North Carolina in Chapel Hill, USA, also postulate: “Alternatively, it may be that the specific FGFR alteration is important and that the increased frequency of R248C mutations among patients with UTUC may have contributed to the higher response rate.”

  8. 14-04-2020 | Guidelines | News | Article
    guidelinesWatch  

    Consensus guidelines released for management of MSI/dMMR, NTRK fusion solid tumors

    In the absence of other satisfactory treatment options, the panel “strongly” recommends that clinicians should give PD-1 inhibitor therapy, such as pembrolizumab, to patients who test positive for MSI/dMMR, and the TRK inhibitors larotrectinib or entrectinib to those with NTRK fusions.

  9. 06-12-2019 | Bladder cancer | Feature | Article

    A closer look at the NCCN patient guidelines for bladder cancer

    Flaig also highlighted the approval by the US FDA of the FGFR inhibitor erdafitinib for muscle-invasive disease harboring FGFR alterations.

  10. 19-08-2019 | FGFR inhibitors | News | Article

    Early data show promise for the FGFR inhibitor rogaratinib

    The FGFR inhibitor rogaratinib is well tolerated and clinically active in patients with various tumor types selected for treatment on the basis of FGFR mRNA overexpression, phase I study data show.

  11. 24-07-2019 | Erdafitinib | News | Article

    Erdafitinib shows promising efficacy in advanced urothelial carcinoma

    The pan-FGFR inhibitor erdafitinib could be a treatment option for previously treated patients with locally advanced or metastatic urothelial carcinoma harboring FGFR aberrations, suggest phase II trial results.

  12. 30-01-2020 | Renal cell carcinoma | News | Article

    Lenvatinib plus pembrolizumab shows promise for RCC and other solid tumors

    In addition, Taylor and co-investigators “plan to study lenvatinib plus pembrolizumab in patients with RCC who have had disease progression after treatment with immune checkpoint inhibitors.” medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature group J Clin Oncol 2020; doi:10.1200/JCO.19. 01598

  13. 05-01-2018 | Immunotherapy | News | Article

    In other news

    Sixty-one patients with tumors harboring FGFR alterations received BGJ398 125 mg/day for 21 days of each 28-day cycle for a median of 4.7 months.

  14. 02-03-2018 | Preclinical | News | Article

    Tumor organoids mirror metastatic GI cancer therapy responses

    For the present study – published in Science – the investigators used biopsy specimens from patients with metastatic GI cancers, including colorectal and gastroesophageal cancer, who were enrolled in the phase II PROSPECT-C or FGFR trials, or in the PROSPECT-R or FOrMAT translational research studies.

  15. 04-08-2016 | Renal cell carcinoma | Article

    Medical treatment of renal cancer: new horizons

    The anti-FGFR and anti-VEGF TKI dovitinib showed no advantage in the third line over sorafenib in patients previously treated with both a TKI and mTOR inhibitor (Motzer  et al , 2014).

  16. 16-11-2016 | Triple-negative breast cancer | Article

    Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants

    TNBCs display the highest rates of pCR following neoadjuvant chemotherapy, 1,28,29,30 with approximately 35–50% of TNBCs achieving pCR following anthracycline+taxane neoadjuvant chemotherapy regimens. 28,30 Importantly, the patients with TNBC who achieve pCR have been shown to have an excellent long-term clinical outcome, with very few distant relapses; on the other hand, patients who have residual disease after neoadjuvant chemotherapy have a poor prognosis. 1,28,29,30 A subset of TNBCs has been suggested to harbor homologous recombination DNA repair defects similar to those found in tumors arising in BRCA1 and BRCA2 mutation carriers. 31 Given that tumors with homologous recombination DNA repair defects may show greater sensitivity to agents that cause DNA double-strand breaks and crosslinks, 32,33 such as platinum salts and inhibitors of the Poly(ADP) Ribose Polymerase (PARP), it has been posited that, as a group, patients with TNBCs may benefit from platinum-based chemotherapy.

  17. 17-08-2016 | Hematologic cancers | Article

    Genomic complexity of multiple myeloma and its clinical implications

    This signalling interaction can be abrogated by combining inhibitors of BRAF and MEK 62 .

  18. 25-07-2015 | Breast cancer | Article

    Precision medicine for metastatic breast cancer—limitations and solutions

    As an illustration, in a randomized trial testing the FGFR-inhibitor dovitinib,  FGFR1, FGFR2  and  FGF3  amplifications were clustered within a single population called “FGF-pathway amplified breast cancer.” 34  Following a similar principle,  BRCA1  and  BRCA2 -mutation carriers are usually clustered together in clinical trials testing PARP inhibitors. 92 The third approach is to perform most of the drug development in the preoperative setting.

  19. 17-05-2016 | Triple-negative breast cancer | Article

    Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease

    MEK inhibitors.  

  20. 01-09-2015 | Staging | Article

    Defining and treating high-risk multiple myeloma

    The emergence of monoclonal antibodies (anti-CS1, anti-CD38, anti-CD138 and so on), along with novel drug classes such as MDM2 inhibitors, KSP inhibitors, XPO-1 inhibitors and FGFR3 inhibitors, affords us the opportunity to combine these new agents with established novel agent regimens especially in the high-risk MM patient population.

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.